|Bid||1.3900 x 2200|
|Ask||1.4000 x 3100|
|Day's Range||1.3600 - 1.4600|
|52 Week Range||0.9900 - 2.2300|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2022 - Aug 19, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
Subscribe to Yahoo Finance Plus to view Fair Value for GERN
What happened Shares of Geron Corporation (NASDAQ: GERN) were soaring 15% higher as of 12:04 p.m. ET on Tuesday. The big gain came after the company provided its first-quarter update following the market close on Monday.
At this time, I would like to welcome everyone to the Geron Corporation first quarter 2022 conference call. Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections including those relating to the therapeutic potential and potential regulatory approval of imetelstat, anticipated clinical and commercial events, and related timelines, the sufficiency of Geron's financial resources, and other statements that are not historical facts.
Geron (GERN) delivered earnings and revenue surprises of 18.18% and 23%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?